title: [Expressions of MicroRNA-96 before and after chemotherapy and its relationship with chemosensitivity in cervical squamous cell carcinoma].
abstract: OBJECTIVE
  To investigate the expression profiles of microRNA-96 (miR-96) in cervical squamous cell carcinoma before and after neoadjuvant chemotherapy and to explore the effects of the treatment on expression of miR-96 and its relationship with clinical efficacy, chemosensitivity, and clinicopathologic features.
  
  
  METHODS
  The expression of miR-96 was detected by real-time polymerase chain reaction in 28 patients with cervical squamous cell carcinoma (stage 1b2-2a) before and after neoadjuvant chemotherapy. The correlations between the change of miR-96 and related clinicopathologic features of cervical cancer (age, pathologic pattern, histological grade, depths of interstitial infiltration, lymph node metastasis, and clinical stage) were further analyzed.
  
  
  RESULTS
  The relative expression of miR-96 in cervical squamous cell carcinoma before treatment was (5.330 ± 5.069) times higher than after the treatment with neoadjuvant chemotherapy (P=0.000).The relative change of the expressions of miR-96 in cervical cancer patients between pre-and post-neoadjuvant chemotherapy was closely related with clinicopathological features:it was significantly smaller in poorly-or moderately-differentiated patients (2.345 ± 1.153) than in well-differentiated patients (9.941 ± 5.359) (P=0.000), significantly larger in patients with the tumor invasion depth < 1/2 interstice (8.236 ± 5.399) than in ≥1/2 interstice (1.978 ± 1.030) (P=0.000), and significantly smaller in patients with lymph node metastasis (1.848 ± 0.959) than those without lymph node metastasis (7.942 ± 5.348) (P=0.000). There was no significant difference in terms of age and clinical stages (1b2-2a) (P>0.05).
  
  
  CONCLUSIONS
  Neoadjuvant chemotherapy can effectively reduce miR-96 expression in cervical squamous cell carcinoma tissues.It is therefore speculated that detection of the miR-96 expression before the chemotherapy for cervical cancer may be helpful to predict the therapeutic efficacy and sensitivity of the treatment.
authors.affiliation: Department of Obstetrics and Gynecology,General Hospital of Guangzhou Military Command,Guangzhou 510010,China.
authors.forename: Wen
authors.initials: W
authors.lastname: Zhou
authors.affiliation: Department of Obstetrics and Gynecology,General Hospital of Guangzhou Military Command,Guangzhou 510010,China.
authors.forename: Ting
authors.initials: T
authors.lastname: Guan
mesh_terms: D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000628:therapy*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000628:therapy*
chemical_list: C541492:MIRN96 microRNA, human; D035683:MicroRNAs